CardiolRx Phase II Results Support Heart Disease Therapy
TORONTO, ON, May 7, 2026 Cardiol Therapeutics Inc. announced that results from its Phase II MAvERIC study evaluating CardiolRx™...
CardiolRx
Advertisement
Cardiol Reaches 50% Enrollment in Phase III MAVERIC Trial
Toronto, Jan. 13, 2026 — Cardiol Therapeutics Inc. announced that it has surpassed the 50% patient enrollment milestone in...
CardiolRx Phase II Trial Shows Structural Heart Recovery in Myocarditis
Toronto, December 1, 2025 — New clinical data from the Phase II ARCHER trial reveal that CardiolRx™, Cardiol Therapeutics’...
Cardiol Therapeutics Gains Major Patent Boost for Heart Drugs
NEW YORK, November 13, 2024 — Cardiol Therapeutics has secured a U.S. patent allowance protecting its next-generation cardiac therapies...
Advertisement
